Stocktoria
Xtant Medical Holdings, Inc. XTNT
Xtant Medical Holdings, Inc. (XTNT) earns a Piotroski F-score of 8/9 (strong financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $133.9M at a 3.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.15 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 8/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.518 |
| Retained earnings / assets | -2.703 |
| EBIT / assets | 0.077 |
| Equity / liabilities | 1.18 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| XTNT | Xtant Medical Holdings, Inc. | 8/9 | -3.66 | 12.7 | +14.2% |
| INFU | InfuSystem Holdings, Inc | 8/9 | 1.27 | 30.1 | +6.4% |
| STIM | Neuronetics, Inc. | 4/9 | -10.38 | — | +99.2% |
| OSUR | ORASURE TECHNOLOGIES INC | 2/9 | 6.76 | — | -38.1% |
| ANIK | Anika Therapeutics, Inc. | 5/9 | 6.68 | — | -5.9% |
| BBNX | Beta Bionics, Inc. | 4/9 | 6.94 | — | +53.9% |
| NPCE | NeuroPace Inc | 5/9 | -13.13 | — | +25.1% |
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.
FAQ
Is XTNT financially healthy?
Xtant Medical Holdings, Inc.'s Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does XTNT pay a dividend?
No, Xtant Medical Holdings, Inc. does not currently pay a dividend.
How profitable is XTNT?
In FY2025, Xtant Medical Holdings, Inc. had a net margin of 3.7% and a return on equity of 9.8%.
What is XTNT's P/E ratio?
Xtant Medical Holdings, Inc.'s trailing price-to-earnings (P/E) ratio is about 12.7×, based on its latest annual earnings.
What is the analyst price target for XTNT?
The average Wall-Street price target for Xtant Medical Holdings, Inc. is $1.23, about 297.3% above the recent price, from 3 analysts.
Is XTNT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Xtant Medical Holdings, Inc.: a Piotroski F-score of 8/9, an Altman Z″ in the distress zone, a P/E of about 12.7×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.